David Levitt, MD
Endocrinology, Diabetes & Metabolism · Hanover, MDNPI 1497020564
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.6%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Abbott at 49.8% of the total. Reporting peaked in 2024 at $4,634 and has fallen 67.2% since, to $1,522 in 2025.
Across 221 payments — averaging $37.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Lilly USA, LLC$602
- Novo Nordisk$541
- Sanofi-aventis U.S. LLC$294
- Amgen$226
- Cequr Corporation$195
- plus $2K from 32 others
What the payments were for
- Consulting fees$1,62520%
- Speaking & faculty fees$2,35628%
- Food & beverage$4,27452%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 15 | $4,127 |
| Lilly USA, LLC | 31 | $602 |
| Novo Nordisk | 36 | $541 |
| Sanofi-aventis U.S. LLC | 16 | $294 |
| Amgen(2 entities) | 11 | $226 |
| Cequr Corporation | 4 | $195 |
| Radius Health, Inc. | 7 | $177 |
| Dexcom, Inc. | 8 | $173 |
| AstraZeneca(2 entities) | 8 | $147 |
| Xeris Pharmaceuticals, Inc. | 9 | $144 |
| Tandem Diabetes Care, Inc. | 5 | $142 |
| Boehringer Ingelheim | 6 | $141 |
| Corcept Therapeutics | 7 | $138 |
| Bayer | 6 | $126 |
| AbbVie | 5 | $118 |
| Madrigal Pharmaceuticals | 3 | $111 |
| BETA Bionics, Inc. | 5 | $106 |
| Antares Pharma, Inc. | 4 | $93 |
| Amneal Pharmaceuticals LLC | 5 | $85 |
| Lifescan, Inc. | 3 | $55 |
| Esperion Therapeutics, Inc. | 2 | $53 |
| Sequel Med Tech, LLC | 2 | $50 |
| Neurocrine Biosciences, Inc. | 2 | $48 |
| Ascensia Diabetes Care US Inc. | 2 | $48 |
| Medtronic | 2 | $44 |
| Mannkind Corporation | 3 | $42 |
| Amarin Pharma, Inc. | 2 | $41 |
| Johnson & Johnson | 2 | $31 |
| Novartis | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| GRT US Holding, Inc. | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Amphastar Pharmaceuticals, Inc. | 1 | $18 |
| Zealand Pharma US, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Valeritas, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$3,981
- CeQur Simplicity$118
How this compares
$8,279 in reported general payments places this provider in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 223 | $436,589 |
| MounjaroTirzepatide | 164 | $234,255 |
| JardianceEmpagliflozin | 114 | $161,251 |
| RybelsusSemaglutide | 81 | $156,618 |
| Tresiba Flextouch U-200Insulin Degludec | 79 | $124,836 |
| TrulicityDulaglutide | 66 | $116,409 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 58 | $83,397 |
| FarxigaDapagliflozin Propanediol | 54 | $72,400 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $58,685 |
| JanuviaSitagliptin Phosphate | 32 | $43,872 |
| Teriparatide | 14 | $42,317 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $36,089 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $35,763 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $33,657 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $25,251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $541 | $606,101335 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $602 | $362,321256 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $141 | $261,087187 claims |
| AstraZenecaFarxiga | $147 | $72,40054 claims |
| AbbVieSynthroid | $118 | $6,75297 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $85 | $3,081272 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Hanover
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
- Eyob MakonnenAnnapolis$205K
- Jawaad KhokharGlen Burnie$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.